News

Sarepta (NASDAQ:SRPT) stock, Replimune (NASDAQ:REPL) stock and Capricor (CAPR) stock surge as FDA's biologics head exits ...
Vinay Prasad, a top FDA official, suddenly departed after a series of controversial decisions about a Duchenne gene therapy ...
Vinay Prasad, M.D., has left the FDA, less than three months into the role as director of the Center for Biologics Evaluation ...
Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F. Kennedy Jr. reportedly plans to dissolve the U.S. Preventive Services Task ...
Regulators block Duchenne muscular dystrophy treatment after fatal side-effects outweigh questionable efficacy ...
After just a few controversial months, Vinay Prasad, MD, MPH, has stepped down as director of FDA's Center for Biologics ...
Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his ...
Dr Vinay Prasad. the U.S. Food and Drug Administration's (FDA) top official, has left the agency just three months after ...
After turning down several new drugs and restricting use of another, Dr. Vinay Prasad drew the ire of the right-wing ...
The MAHA-aligned Food and Drug Administration official responsible for overseeing vaccine and gene therapy approvals has been ...
Prasad, an oncologist who previously criticised the FDA and was a fierce critic of US Covid-19 vaccine and mask mandates, had ...
Vinay Prasad, the top official at the U.S. FDA, resigns after three tumultuous months. Known for his criticism of COVID-19 mandates, Prasad's tenure saw controversial regulatory actions. His departure ...